Pharming and Hyupjin Corporation announce commercialisation agreement for RUCONEST in Korea
(Thomson Reuters ONE) -
Leiden, The Netherlands, March 26, 2012. Biotech company Pharming Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today that it has
entered into an agreement with Hyupjin Corporation, a Seoul based Korean
specialty pharma company, to commercialise RUCONEST(®) (recombinant human C1
inhibitor) for the treatment of acute attacks of Hereditary Angioedema (HAE) in
the Republic of Korea.
Under the agreement, Hyupjin will drive the regulatory approval in Korea and
purchase its commercial supplies of RUCONEST from Pharming at a fixed transfer
price.
"The collaboration with a well-established company such as Hyupjin Corporation,
as part of our ongoing efforts to extend the commercialisation of RUCONEST is
very exciting for us" said Sijmen de Vries, CEO of Pharming. "We are very much
looking forward to having RUCONEST distributed by such an experienced partner in
Korea. With this agreement with Hyupjin Corporation, we now have two strong
partners in Asia for the distribution of RUCONEST, whilst discussions continue
with potential partners for other territories."
Mr. Macsan Cho, General Manager of Hyupjin Corporation, said: "In our continuous
effort to bring the most innovative therapeutics to patients, this agreement to
distribute RUCONEST will now enable us to provide the Korean HAE patients access
to this most innovative way to treat their disease. Given our long established
relationships in immunology, we feel that RUCONEST complements our existing
product portfolio very well and we look forward to getting started."
About RUCONEST (RHUCIN in non-European territories) and Hereditary Angioedema
RUCONEST(®) (INN conestat alfa) is a recombinant version of the human protein C1
inhibitor (C1INH). RUCONEST is produced through Pharming's proprietary
technology in milk of transgenic rabbits and in Europe is approved under the
name RUCONESTfor treatment of acute angioedema attacks in patients with HAE.
RHUCIN(®) is an investigational drug in the U.S. and has been granted orphan
drug designation for the treatment of acute attacks of HAE, a genetic disorder
in which the patient is deficient in or lacks a functional plasma protein C1
inhibitor, resulting in unpredictable and debilitating episodes of intense
swelling of the extremities, face, trunk, genitals, abdomen and upper airway.
The frequency and severity of HAE attacks vary and are most serious when they
involve laryngeal edema, which can close the upper airway and cause death by
asphyxiation. According to the U.S. Hereditary Angioedema Association,
epidemiological estimates for HAE range from one in 10,000 to one in 50,000
individuals.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of unmet
medical needs. RUCONEST® (RHUCIN® in non-European territories) is a recombinant
human C1 inhibitor approved for the treatment of angioedema attacks in patients
with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is
distributed in the EU by Swedish Orphan Biovitrum (OMX: SOBI). RHUCIN® is
partnered with Santarus, Inc (NASDAQ: SNTS) in North America where the drug is
undergoing Phase III clinical development. The product is also being evaluated
for follow-on indications in the areas of transplantation and reperfusion
injury. The advanced technologies of the Company include innovative and
validated platforms for the production of protein therapeutics, technology and
processes for the purification and formulation of these products. A feasibility
study, using the validated transgenic rabbit platform, aimed at the development
of recombinant Factor VIII for the treatment of Haemophilia A is underway with
partner, Renova Life, Inc. Additional information is available on the Pharming
website, www.pharming.com.
About Hyupjin Corporation
Headquartered in Seoul, Korea, Hyupjin Corporation develops and distributes
healthcare products from prominent companies in the USA and Europe since 1975.
With 30 years of experience in the medical market, Hyupjin Corporation has tight
relationships with healthcare professionals and has built extensive know-how of
the medical community. Hyupjin's product portfolio mainly consists of oncology
and immunology products, but also OTCs, dietary supplements and medical devices.
Hyupjin has made a consistent effort for the treatment of incurable diseases
along with improvement of patient's quality of life. For more information,
please visit http://www.hyupjincorp.com/index_en.php.
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact
Sijmen de Vries, CEO: T: +31 (0) 71 524 7400
Karl Keegan, CFO: T: +31 (0) 71 524 7400
FTI Consulting
Julia Phillips/ John Dineen, T: +44 (0)207 269 7193
# # #
Press release (PDF):
http://hugin.info/132866/R/1597046/503390.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE
[HUG#1597046]
Unternehmensinformation / Kurzprofil:
Datum: 26.03.2012 - 07:00 Uhr
Sprache: Deutsch
News-ID 128085
Anzahl Zeichen: 6231
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 161 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharming and Hyupjin Corporation announce commercialisation agreement for RUCONEST in Korea"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
